$SCNX News

Maxim Group Maintains Buy on Scienture Holdings, Adjusts Price Target To $6 (reverse stock split 1:25)

SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027

Scienture Holdings Reports Preliminary Q3 Revenue Growth To $1.22M; Co Targeting Profitability In 2027

SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions

Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened

Scienture Holdings, Inc. Announces Reverse Stock Split

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

SCIENTURE To Provide REZENOPY To Addiction Treatment Centers

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US

EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US

Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why